Table 2.
Risk of long-term adverse outcomes by CID status in TORCH and ECLIPSE [48]
| Outcome | TORCH (n = 5292) | ECLIPSE (n = 1953) | ||||
|---|---|---|---|---|---|---|
| CID+ at 6 months [N = 2870], n (%) |
CID- at 6 months [N = 2422], n (%) |
% risk increase assessed at 7–36 months (95% CI) |
CID+ at 12 months [N = 1442], n (%) |
CID- at 12 months [N = 531], n (%) |
% risk increase assessed at 13–36 months (95% CI) |
|
| Moderate/severe exacerbation | 2082 (73) | 1450 (60) | 61 (50, 72) | 1082 (75) | 232 (44) | 154 (120, 193) |
| Hospital admission for severe exacerbations | 797 (28) | 491 (20) | 55 (38, 73) | 454 (31) | 66 (12) | 181 (117, 263) |
| All-cause mortality | 237 (8) | 160 (7) | 41 (15, 72) | 121 (8) | 27 (5) | 59 (4, 141) |
CID was defined as: FEV1, deterioration ≥ 100 mL or SGRQ deterioration ≥ 4 units or a first moderate/severe exacerbation on any treatment in both trials. All comparisons are for CID+ versus CID- cohorts. p < 0.05 for all risk increases in both trials
CI confidence interval, CID clinically important deterioration; CID+ cohort with a short-term deterioration (i.e. early unstable cohort); CID- cohort without a short-term deterioration (i.e. early stable cohort)